Inclusion Criteria:

• A patient with at least one soft-tissue liver lesion less than or equal to 5 cm undergoing microwave ablation using the NEUWAVE Microwave Ablation System.
  • Note: a patient cannot have more than 3 lesions ablated during the procedure.
• Intent to use Ablation Confirmation software (any AC software version permitted) during the ablation procedure.
• Written Informed Consent to voluntarily participate in the study, follow CT scan schedule, and authorize the transfer of his/her data to the Sponsor.
• Patients greater than or equal to 18 years of age.
• Performance status 0-2 (Eastern Cooperative Oncology Group [ECOG]) classification.
• Class A or B functional hepatic reserve based on the Child-Pugh score.
• Lesion must be visualized by non-contrast enhanced CT scan or the patient must tolerate contrast and meet institutional guidelines for contrast use based on glomerular filtration rate (GFR).

Exclusion Criteria:

• Active bacterial infection or fungal infection on the day of the ablation.
• Patients with implantable pacemakers or other electronic implants.
• Platelet count less than 50,000/mm cubed.
• Patients with uncorrectable coagulopathy at the time of ablation.
• Currently breastfeeding or pregnant (latter confirmed by serum pregnancy test).
• Physical or psychological condition which would impair study participation.
• ASA (American Society of Anesthesiologists) score of great or equal to 4.
• Use of hydrodissection.
• Systemic administration (intravenous or oral) of steroids, including herbal supplements, that contain steroids, within 30 days prior to the study ablation procedure.
• Chemotherapy or radiation therapy, within 30 days prior to the study ablation procedure.
• INR greater than 1.5.
• Patient has participated in an investigational clinical study within 30 days of the screening visit for this study.
• Patient judged unsuitable for study participation by the performing physician for any other reason.